doi: 10.2337/dc16-S016 [PubMed] 27099902 Bansal N, Weinstock RS
Initial take-up is reported to be strong, and the company said during its fourth-quarter results update this week that around 50,000 prescriptions are currently being filled each week
However, the numerous central effects described for native GLP-1 and for some of the GLP-1RAs in rodents and in humans encourage future clinical trials exploring additional mechanisms that could potentially underlie the beneficial effects observed with this drug class
No proven upside to offset even mild risk: When benefit is uncertain, small and infrequent risks matter more Lipo-C should not displace interventions with strong outcome data (diet, activity, and, where indicated, approved pharmacotherapy)
The greatest testament youll ever have of an organization is its like the hair club for men